Information Provided By: 
Fly News Breaks for November 11, 2016
RTRX
Nov 11, 2016 | 08:01 EDT
Leerink analyst Joseph Schwartz says that the trial design for Retrophin's pending Phase 3 trial of RE-024 and the announced agreement with the FDA under the Special Protocol Assessment process for this trial bode well for potential approval in 2019. The analyst believes the company plans to initiate this trial by the end of 2016, with a drug that has shown "great promise" for the treatment of pantothenate kinase-associated neurodegeneration. He reiterates an Outperform rating on the shares.
News For RTRX From the Last 2 Days
There are no results for your query RTRX
